Aanvaard alle cookies en geniet van de beste ervaring op onze website, zoals contentpersonalisatie en functies voor social media. Aanvaard enkel noodzakelijke cookies en ga voor minimaal gebruik van cookies terwijl je browst. Dit betekent wel dat sommige delen van de website mogelijk niet correct worden weergeven. Meer weten? Raadpleeg ons Privacybeleid.
The sessions offered this year had covered pharmaceuticals, biotechnology and medical products. It had been an opportunity to exchange views and to discuss new technologies, new legislation and their implementation, as well as new information on patient tools in a collegial environment where improving health is the common goal.
A wide variety of sessions was offered, with topics ranging from early development to market access. They included:
- Health technology assessment – more targeted medicines and specialty technologies
- Lifecycle benefit risk management – evidence for market access and efficacy assessments
- Special populations – requirements adapted for pediatrics and geriatrics
- Availability of medicinal products – marketing authorization and drug availability
- Clinical trials – operation of efficacy and personalized medicines
- Medical writing - information to patients – balance between ‘too long and too short”
- Big data / e-Health – opportunities and challenges of access to patient data
- Medical affairs – better interaction between stakeholders via novel technologies
Location
Hamburg, Germany
